Kornblith, PK, Welch, WC, Bradley, MK. The future therapy forglioblastoma. Surgical Neurol
1993; 39: 538–543.
Yung, WKA. New approaches to molecular therapy of brain tumors.Curr Op Neurol
1994; 7: 501–505.
Ettinghausen, SE, Rosenberg, SA. Immunotherapy and gene therapyof cancer. Adv Surg
1995; 28: 223–254.
Parney, IF, Hao, C, Petruk, KC. Glioma immunology andimmunotherapy: a review. Neurosurgery
2000; 46: 778–792.
Parney, IF, Farr-Jones, MA, Chang, L-J, Petruk, KC. Human gliomaimmunobiology in vitro: implications for immunogene therapy. Neurosurgery
2000; 46: 1169–1178.
Siepl, C, Bodmer, S, Frei, K, et al.
The glioblastoma derived T-cellsuppressor factor/transforming growth factor beta 2 inhibits T-cell growth without affecting the interaction of interleukin-2 withits receptor. Eur J Immunol
1988; 18: 593–600.
Kuppner, M, Hamou, M, Sawamura, Y, Bodmer, S, de Tribolet, N. Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor beta 2. J Neurosurg
1989; 71: 211–217.
Bodmer, S, Strommer, K, Frei, K, et al.
Immunosuppression andtransforming growth factor beta in glioblastoma: preferential production of transforming growth factor beta 2. J Immunol
1989; 143: 3222–3229.
Fontana, A, Kristensen, F, Dubs, R, Gemsa, D, Weber, E. Production ofprostaglandin E and interleukin-1 like factor by cultured astrocytes and C6 glioma cells. J Immunol
1982; 129: 2413–2419.
Sawamura, Y, Diserens, A-C, de Tribolet, N. In vitro Prostaglandin E2production by glioblastoma cells and its effect on interleukin-2 activation of oncolytic lymphocytes. J Neurooncol
1990; 9: 125–130.
Hao, C, Parney, IF, Ramsay, DA, et al.
Cytokine and cytokinereceptor mRNA expression in human glioblastoma tumors and cell lines. Acta Neuropathol (Berl)
2001; In Press.
Plate, KH, Risau, W. Angiogenesis in malignant gliomas. Glia
1995; 15: 339–347.
Wesseling, P, Ruiter, DJ, Burger, PC. Angiogenesis in brain tumors;pathological and clinical aspects. J Neurooncol
1997; 32: 253–265.
Grabilovich, DI, Chen, HL, Girgis, KR, et al.
Production of vascularendothelial growth factor by human tumors inhibits thefunctional maturation of dendritic cells. Nature Med
1996; 2: 1096–1103.
Fakhrai, H, Dorigo, O, Shawler, DL, et al.
Eradication of establishedintracranial rat gliomas by transforming growth factor betaantisense gene therapy. PNAS
1996; 93: 2909–2914.
Dranoff, G, Jaffee, E, Lazenby, A, et al.
Vaccination with irradiatedtumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific and long lasting anti-tumor immunity. PNAS
1993; 90: 3539–3543.
Sampson, JH, Archer, GE, Ashley, DM, et al.
Subcutaneousvaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the “immunologically privileged” central nervous system. PNAS
1996; 93: 10399–10404.
Yu, JS, Burwick, JA, Dranoff, G, Breakefield, XO. Gene therapy formetastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells. Hum Gene Ther
1997; 8: 1065–1072.
Parney, IF, Petruk, KC, Zhang, C, et al.
GM-CSF and B7-2combination immunogene therapy in an allogeneic hu-PBL-SCID/beige mouse-human glioblastoma multiforme model. HumGene Ther
1997; 8: 1073–1085.
Parney, IF, Farr-Jones, MA, Koshal, A, Chang, L-J, Petruk, KC. Human brain tumor cell culture characterization following immunostimulatory gene transfer. Neurosurgery
2002; In press.
Gainer, AL, Young, ATL, Parney, IF, Petruk, KC, Elliott, JF. Gene-guntransfection of human glioma and melanoma cell lines with genesencoding human IL-12 and GM-CSF. J Neurooncol
2000; 47: 23–30.
Lieshcke, G, Burgess, A. Granulocyte colony-stimulating factor andgranulocyte-macrophage colony-stimulating factor (part I). NEJM
1992; 327: 28–35.
Aglietta, M, Piacibello, W, Pasquino, P, et al.
Rationale for the use ofgranulocyte-macrophage colony-stimulating factor. Semin Oncol
1994; 21: 5–9.
Engelhard, M, Brittinger, G. Clinical relevance of granulocyte-macrophage colony-stimulating factor. Semin Oncol
1994; 21: 1–4.
Hanada, K, Tsunoda, R, Hamada, H. GM-CSF-induced in vivoexpansion of splenic dendritic cells and their strong costimulation activity. J Leukocyte Biol
1996; 60: 181–190.
Brunda, MJ. Interleukin-12. J Leukocyte Biol
1994; 55: 280–288.
Tahara, H, Lotze, MT. Antitumor effects of interleukin-12 (IL-12):applications for the immunotherapy and gene therapy of cancer. Gene Ther
1995; 2: 96–106.
Tahara, H, Lotze, MT, Robbins, PD, Storkus, WJ, Zitvogel, L. ClinicalProtocol: IL-12 gene therapy using direct injection of tumors with genetically engineered autologous fibroblasts. Hum Gene Ther
1995; 6: 1607–1624.
Li, Y, McGowan, P, Hellstrom, I, Hellstrom, KE, Chen, L. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J Immunol
1994; 153: 421–427.
Freeman, G, Gribben, J, Baussioties, V, et al.
Cloning of B7-2: aCTLA-4 counter-receptor that costimulates human T-cell proliferation. Science
1993; 262: 909–911.
Chen, L, Ashe, S, Brady, W, et al.
Costimulation of antitumorimmunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell
1992; 71: 1093–1102.
Lanier, L, O’Fallon, S, Somoza, C, et al.
CD80 (B7) and CD86 (B70)provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. J Immunol
1995; 154: 97–105.
Mondino, A, Jenkins, MK. Surface proteins involved in T cellcostimulation. J Leukocyte Biol
1994; 55: 805–815.
June, C, Bluestone, J, Nadler, L. The B7 and CD28 receptor families. Immunol Today
1994; 15: 321–331.
Yang, G, Hellstrom, KE, Hellstrom, I, Chen, L. Antitumor immunityelicited by tumor cells transfected with B7-2, a second ligand forCD28/CTLA-4 costimulatory molecules. J Immunol
1995; 154: 2794–2800.
Plumas, J, Chaperot, L, Jacob, M-C, et al.
Malignant B lymphocytesfrom non-Hodgkin’s lymphoma induce allogeneic proliferative and cytotoxic T cell responses in primary mixed lymphocyte cultures: an important role of costimulatory molecules CD80 (B7-1) and CD86 (B7-2) in stimulation by tumor cells. Eur JImmunol
1995; 25: 3332–3341.
Glick, RP, Lichtor, T, Mogharbel, A, Taylor, CA, Cohen, EP. Intracerebral versus subcutaneous immunization with allogeneic fibroblasts genetically engineered to secrete interleukin-2 in the treatment of central nervous system glioma and melanoma. Neurosurgery
1997; 41: 898–907.
Glick, RP, Lichtor, T, Kim, TS, Ilangovan, S, Cohen, EP. Fibroblastsgenetically engineered to secrete cytokines suppress tumor growth and induce antitumor immunity to a murine glioma in vivo. Neurosurgery
1995; 36: 548–555.
Auer, RN, Del Maestro, RF, Anderson, R. A simple and reproducibleexperimental in vivo glioma model. Can J Neurol Sci
Hamilton, D, McKean, JDS, Tulip, J, Boisvert, D, Cummins, J. In vitrophotoradiation therapy of rat 9L gliosarcoma. J Neurosurg
1986; 64: 775–779.
Krushelnycky, BW, Farr-Jones, MA, Mielke, B, et al.
Development ofa large-animal human brain tumor xenograft model in immunosuppressed cats. Cancer Res
1991; 51: 2430–2437.
Parney, IF, Farr-Jones, MA, Petruk, KC. Improved technique forestablishing short term human brain tumor cultures. J Neurooncol
1999; 43: 1–10.
Robinson, D, Elliott, JF, Chang, LJ. Retroviral vector with a CMV-IE/HIV-TAR hybrid LTR gives high basal expression levels andis upregulated by HIV-1 Tat. Gene Ther
1995; 2: 269–278.
Miller, AD, Buttimore, C. Redesign of retrovirus packaging cell linesto avoid recombination leading to helper virus production. Molec Cell Biol
1986; 6: 2895–2902.
Miller, AD, Miller, DG, Garcia, JV, Lynch, CM. Use of retroviralvectors for gene transfer and expression. Meth Enzymol
1993; 217: 581–599.
King, C, Hoenger, RM, Cleary, MM, et al.
Interleukin-4 acts at thelocus of the antigen-presenting dendritic cell to counter-regulatecytotoxic CD8+ T-cell responses. Nature Med
2001; 7: 206–214.
Badie, B, Schartner, JM, Paul, J, et al.
Dexamethasone-inducedabolition of the inflammatory response in an experimental glioma model: a flow cytometry study. J Neurosurg
2000; 93: 634–639.
Roszman, T, Elliott, L, Brooks, W. Modulation of T-cell function bygliomas. Immunol Today
1991; 12: 370–374.
Morford, LA, Elliott, LH, Carlson, SL, Brooks, WH, Roszman, TL. Tcell receptor-mediated signalling is defective in T cells obtained from patients with primary intracranial tumors. J Immunol
1997; 159: 4415–4425.
Lee, PP, Yee, C, Savage, PA, et al.
Characterization of circulating Tcells specific for tumor-associated antigens in melanoma patients. Nature Med
1999; 5: 677–685.
Kurpad, SN, Zhao, X-G, Wikstrand, CJ, et al.
Tumor antigens inastrocytic gliomas. Glia
1995; 15: 244–256.
Lampson, LA. Immunobiology of brain tumors: antigens, effectors,and delivery to sites of microscopic tumor in the brain. In: Black, PM, Loeffler, (Eds.), Cancer of the Nervous System. Blackwell Science, Inc., 1997.
Sobol, RE, Fakhrai, H, Shawler, D, et al.
Interleukin-2 gene therapyin a patient with glioblastoma. Gene Ther
1995; 2: 164–167.
Ellem, KAO, O’Rourke, MGE, Johnson, GR, et al.
A case report:immune responses and clinical course of the first human use of granulocyte-macrophage colony-stimulating factor-transduced autologous melanoma cells for immunotherapy. Cancer ImmunolImmunother
1997; 44: 10–20.